Contribution of Beta 1- and Beta 2-adrenoceptors of Human Atrium and Ventricle to the Effects of Noradrenaline and Adrenaline As Assessed with (-)-atenolol

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1988 Sep 1

PMID 2851354

Citations 19

Authors

H Lemoine

H Schonell

A J Kaumann

Affiliations

Soon will be listed here.

Abstract

1. (-)-Atenolol was used as a tool to assess the function of beta 1- and beta 2-adrenoceptors in human heart. Right atrial and left ventricular preparations from patients undergoing open heart surgery were set up to contract isometrically. Membrane particles were prepared for beta-adrenoceptor labelling with [3H]-(-)-bupranolol and adenylate cyclase assays. 2. The positive inotropic effects of (-)-noradrenaline were antagonized to a similar extent by (-)-atenolol in atrial and ventricular preparations. (-)-Atenolol consistently antagonized the effects of (-)-adrenaline to a lesser extent than those of (-)-noradrenaline in atrial preparations. In ventricular preparations (-)-atenolol antagonized the effects of low concentrations of (-)-adrenaline to a lesser extent than those of high concentrations. 3. pKB values (M) of (-)-atenolol, estimated with non-linear analysis from the blockade of the positive inotropic effects of the catecholamines, were 7.4 for beta 1-adrenoceptors and 6.0 for beta 2-adrenoceptors. 4. (-)-Atenolol inhibited the binding of [3H]-(-)-bupranolol to ventricular beta 1-adrenoceptors with a pKD (M) of 5.9 and to ventricular beta 2-adrenoceptors with a pKD of 4.6. 5. (-)-Atenolol inhibited the catecholamine-induced adenylate cyclase stimulation in the atrium and ventricle with pKB values of 5.8-6.4 for beta 1- and pKB values of 4.7-5.7 for beta 2-adrenoceptors. The binding and cyclase assays suggest a partial affinity loss for (-)-atenolol inherent to membrane preparations. 6. beta 1-Adrenoceptors mediate the maximum positive inotropic effects of (-)-noradrenaline in both the atrium and ventricle of man. beta 2-Adrenoceptors appear to be capable of mediating maximal positive inotropic effects of (-)-adrenaline in atrium. In contrast, ventricular beta 2-adrenoceptors mediated only submaximal effects of (-)-adrenaline.

Citing Articles

Poor Sympathetic Compensation During Active Standing Increases the Risk of Morbidity-Mortality in the Post-Surgery of Patients with Severe Calcific Aortic Stenosis.

Avila-Vanzzini N, Santana-Ortiz A, Sanchez-Estrada D, Springall R, Lerma A, Herrera-Bello H Biology (Basel). 2025; 14(2).

PMID: 40001914 PMC: 11851686. DOI: 10.3390/biology14020146.

Effect of adrenaline on serum mid-regional pro-atrial natriuretic peptide and central blood volume.

Sejersen C, Bjerre-Bastos J, Goetze J, Nielsen H, Bihlet A, Secher N Exp Physiol. 2022; 107(9):1037-1045.

PMID: 35912634 PMC: 9545049. DOI: 10.1113/EP090516.

Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes.

Saleem U, van Meer B, Katili P, Mohd Yusof N, Mannhardt I, Krotenberg Garcia A Toxicol Sci. 2020; 176(1):103-123.

PMID: 32421822 PMC: 7357169. DOI: 10.1093/toxsci/kfaa058.

β 1 Adrenoceptor antagonistic effects of the supposedly selective β 2 adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts.

Pecha S, Flenner F, Sohren K, Lorenz K, Eschenhagen T, Christ T Pharmacol Res Perspect. 2015; 3(5):e00168.

PMID: 26516580 PMC: 4618639. DOI: 10.1002/prp2.168.

Homology model and docking studies on porcine β₂ adrenoceptor: description of two binding sites.

Soriano-Ursua M, Correa-Basurto J, Trujillo-Ferrara J, Kaumann A J Mol Model. 2011; 17(10):2525-38.

PMID: 21203789 DOI: 10.1007/s00894-010-0915-1.

References

Zerkowski H, Ikezono K, Rohm N, REIDEMEISTER J, Brodde O . Human myocardial beta-adrenoceptors: demonstration of both beta 1- and beta 2-adrenoceptors mediating contractile responses to beta-agonists on the isolated right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(2):142-7. DOI: 10.1007/BF00511404. View

Gille E, Lemoine H, Ehle B, Kaumann A . The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1985; 331(1):60-70. DOI: 10.1007/BF00498852. View

Rehling M, Svendsen T, Maltbaek N, Tango M, TRAP-JENSEN J . Haemodynamic effects of atenolol, pindolol and propranolol during adrenaline infusion in man. Eur J Clin Pharmacol. 1986; 30(6):659-63. DOI: 10.1007/BF00608212. View

Heitz A, Schwartz J, VELLY J . Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol. 1983; 80(4):711-7. PMC: 2045057. DOI: 10.1111/j.1476-5381.1983.tb10062.x. View

Kaumann A, Lobnig B . Mode of action of (-)-pindolol on feline and human myocardium. Br J Pharmacol. 1986; 89(1):207-18. PMC: 1917032. DOI: 10.1111/j.1476-5381.1986.tb11137.x. View

Kaumann A, Lemoine H . Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol. 1987; 335(4):403-11. DOI: 10.1007/BF00165555. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

STEPHENSON R . A modification of receptor theory. Br J Pharmacol Chemother. 1956; 11(4):379-93. PMC: 1510558. DOI: 10.1111/j.1476-5381.1956.tb00006.x. View

BLINKS J . Convenient apparatus for recording contractions of isolated heart muscle. J Appl Physiol. 1965; 20(4):755-7. DOI: 10.1152/jappl.1965.20.4.755. View

10.

Salomon Y, Londos C, Rodbell M . A highly sensitive adenylate cyclase assay. Anal Biochem. 1974; 58(2):541-8. DOI: 10.1016/0003-2697(74)90222-x. View

11.

Kaumann A, Birnbaumer L . Studies on receptor-mediated activation of adenylyl cyclases. IV. Characteristics of the adrenergic receptor coupled to myocardial adenylyl cyclase: stereospecificity for ligands and determination of apparent affinity constants for beta-blockers. J Biol Chem. 1974; 249(24):7874-85. View

12.

Conway F, Fitzgerald J, Mcainsh J, Rowlands D, SIMPSON W . Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol. 1976; 3(2):267-72. PMC: 1428868. DOI: 10.1111/j.1365-2125.1976.tb00602.x. View

13.

Mcainsh J . Clinical pharmacokinetics of atenolol. Postgrad Med J. 1977; 53 Suppl 3:74-8. View

14.

Kaumann A . On spare beta-adrenoceptors of inotropic effect of catecholamines in kitten ventricle. Naunyn Schmiedebergs Arch Pharmacol. 1978; 305(2):97-102. DOI: 10.1007/BF00508277. View

15.

Kaumann A, BLINKS J . Stimulant and depressant effects of beta-adrenoceptor blocking agents on isolated heart muscle. A positive inotropic effect not mediated through andrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1980; 311(3):205-18. DOI: 10.1007/BF00569401. View

16.

Morris T, Sandrock K, Kaumann A . 3H-(-)-Bupranolol, a new beta-adrenoceptor radioligand: characterization of its binding to kitten heart beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1981; 317(1):19-25. DOI: 10.1007/BF00506251. View

17.

Kaumann A, Marano M . On equilibrium dissociation constants for complexes of drug-receptor subtypes. Selective and non-selective interactions of partial agonists with two plausible beta-adrenoceptor subtypes mediating positive chronotropic effects of (-)-isoprenaline in.... Naunyn Schmiedebergs Arch Pharmacol. 1982; 318(3):192-201. DOI: 10.1007/BF00500480. View

18.

Lemoine H, Kaumann A . A novel analysis of concentration-dependence of partial agonism Ring-demethylation of bupranolol results in a high affinity partial agonist (K 105) for myocardial and tracheal beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1982; 320(2):130-44. DOI: 10.1007/BF00506313. View

19.

Kaumann A, Morris T, Bojar H . Heart beta-receptors: on the functional role of heterogeneous binding sites. J Recept Res. 1983; 3(1-2):61-70. DOI: 10.3109/10799898309041923. View

20.

Lemoine H, Kaumann A . A model for the interaction of competitive antagonists with two receptor-subtypes characterized by a Schild-plot with apparent slope unity. Agonist-dependent enantiomeric affinity ratios for bupranolol in tracheae but not in right atria of guinea.... Naunyn Schmiedebergs Arch Pharmacol. 1983; 322(2):111-20. DOI: 10.1007/BF00512383. View